Arena Pharmaceuticals (ARNA) Shares are Up 0.57%

Arena Pharmaceuticals (ARNA) : Traders are bullish on Arena Pharmaceuticals (ARNA) as it has outperformed the S&P 500 by a wide margin of 12.07% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.41%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.57% in the last 1 week, and is up 11.47% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 5.93% and the 50-Day Moving Average is 5.62%.The 200 Day SMA reached 3.02%


Arena Pharmaceuticals (NASDAQ:ARNA): The stock was completely flat for the day, closing at $1.75 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.78, the stock touched an intraday high of $1.80 and a low of $1.72. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.75. The total trading volume on Friday was 2,449,560.

Arena Pharmaceuticals (ARNA) : The highest short term price target forecast on Arena Pharmaceuticals (ARNA) is $6 and the lowest target price is $4. A total of 3 equity analysts are currently covering the company. The average price of all the analysts is $4.5 with a standard deviation of $1.32.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *